Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States and Iran and accelerated investment in artificial intelligence (AI) fueled market optimism in the quarter, driving the Information Technology and Industrials sectors forward while Energy and Utilities lagged due to falling oil and gas prices. In June, the Federal Reserve maintained steady interest rates, but the meeting had a hawkish tone. As AI transitions into its agentic phase, opportunities are identified within sectors adopting the technology. The Alger Small Cap Focus Fund’s Class A shares outperformed the Russell 2000 Growth Index in the quarter, driven by strong performances in the Industrials and Health Care sectors, while Financials and Consumer Discretionary detracted from the performance. In addition, please check the Fund’s top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Alger Small Cap Focus Fund highlighted GeneDx Holdings Corp. (NASDAQ:WGS). GeneDx Holdings Corp. (NASDAQ:WGS) is a genomics company that offers advanced exome and genome sequencing for pediatric and rare disease diagnostics. On July 20, 2026, GeneDx Holdings Corp. (NASDAQ:WGS) closed at $60.65 per share, reflecting a market capitalization of $1.80 billion. GeneDx Holdings Corp. (NASDAQ:WGS) posted a one-month return of 4.42%, while its shares lost 25.03% over the past 52 weeks.
Alger Small Cap Focus Fund stated the following regarding GeneDx Holdings Corp. (NASDAQ:WGS) in its Q2 2026 investor update:
“GeneDx Holdings Corp. (NASDAQ:WGS) is a specialty genomics laboratory focused on delivering complex genetic tests, including whole exome and genome sequencing, to diagnose pediatric rare diseases. The company possesses a comprehensive and proprietary database of genetic data that enables it to deliver superior diagnostic yields relative to competitors and alternative testing modalities, creating a meaningful competitive advantage in a highly specialized market. Shares detracted from performance after first-quarter results missed revenue expectations on softer average reimbursement rates and weakness in non-core segments. While underlying exome and genome test volumes grew 33% year over year, management lowered full-year guidance, weighing on investor sentiment.”
GeneDx Holdings Corp. (NASDAQ:WGS) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 37 hedge fund portfolios held GeneDx Holdings Corp. (NASDAQ:WGS) at the end of the first quarter, up from 39 in the previous quarter. In Q1 2026, GeneDx Holdings Corp.’s (NASDAQ:WGS) total revenue came in $102.3 million, which was $12 million lower than expected, despite stronger than expected volume growth. While we acknowledge the risk and potential of GeneDx Holdings Corp. (NASDAQ:WGS) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GeneDx Holdings Corp. (NASDAQ:WGS) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered GeneDx Holdings Corp. (NASDAQ:WGS) and shared Polen 5Perspectives Small Growth Strategy’s views on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
